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Abstract 
Osteosarcoma is the most common bone tumors which consisted of malignant mesenchymal cells generating oste-
oid and immature bone. It has been showed that osteosarcoma is common in children and adolescents and shows 
high mortality rate. A variety of therapeutic approaches (i.e., resection surgery, combined with chemotherapy and 
radiotherapy) have been used as conventional treatments in patients with osteosarcoma. Despite several attempts 
to improve therapeutic response, the rate of survival for osteosarcoma has not changed during the past 3 decades. 
Therefore, the discovery and developing new effective therapeutic platforms are required. Along to the established 
anti-cancer agents, some physiological regulators such melatonin, have been emerged as new anti-cancer agents. 
Melatonin is an indolamine hormone which is secreted from the pineal glands during the night and acts as physio-
logical regulator. Given that melatonin shows a wide spectrum anti-tumor impacts. Besides different biologic activities 
of melatonin (e.g., immunomodulation and antioxidant properties), melatonin has a crucial role in the formation of 
bones, and its deficiency could be directly related to bone cancers. Several in vitro and in vivo experiments evaluated 
the effects of melatonin on osteosarcoma and other types of bone cancer. Taken together, the results of these studies 
indicated that melatonin could be introduced as new therapeutic candidate or as adjuvant in combination with other 
anti-tumor agents in the treatment of osteosarcoma. Herein, we summarized the anti-tumor effects of melatonin for 
osteosarcoma cancer as well as its mechanism of action.
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Introduction
Osteosarcoma is known as the most common aggressive 
and malignant tumor from bone. It usually occurs in the 
metaphysis of long bones and happens predominantly 
in children and adolescents [1]. Although the causes of 
osteosarcoma have not yet been fully elucidated, there is 
probably a correlation between the rate of bone growth 
during puberty and the incidence of this disease [2]. It 
has also been seen that young patients with osteosar-
coma are usually taller than healthy subjects in similar 
age groups [1, 3]. Osteosarcoma accounted for approxi-
mately 5% of childhood cancers and also almost 8.9% of 
childhood cancer-related deaths. The incidence of osteo-
sarcoma is estimated at 5 per million people [4]. Ewing 
sarcoma is another type of secondary bone cancer which 
occurred more often in adolescents [5]. In this kind of 
cancer, the survival rate is about 50% in 5 years after the 
initial diagnosis [6].
Conventional therapies for osteosarcoma consisted 
of a combination of surgery and adjuvant and neoadju-
vant chemotherapy [7]. Given that before utilization of 
chemotherapy, less than a 20% survival rate in high-grade 
conventional osteosarcoma even with surgical amputa-
tion, revealing the existence of micrometastases before 
surgery [8]. The low grade could be treated with exci-
sion alone and chemotherapy is avoided if final pathology 
confirms low grade [8].
Treatments that are used for bone cancers are not asso-
ciated with effective results and are not able to increase 
the survival rate [9]. On the other hand, the used thera-
peutic platforms are related to various side effects [10]. 
Open Access
Cancer Cell International
*Correspondence:  h.mirzaei2002@gmail.com; mirzaei-h@kaums.ac.ir; 
Asemi_r@yahoo.com
2 Research Center for Biochemistry and Nutrition in Metabolic Diseases, 
Institute for Basic Sciences, Kashan University of Medical Sciences, 
Kashan, Islamic Republic of Iran
Full list of author information is available at the end of the article
Page 2 of 8Fathizadeh et al. Cancer Cell Int          (2019) 19:319 
Therefore, novel therapeutic approaches with less or no 
adverse effects are needed in the treatment of osteosar-
coma patients [11].
Melatonin, N-acetyl-5-methoxy-tryptamine, plays 
significant roles in different physiological events such 
as regulating the sleep–wake cycle, declining of tumor 
progress, ameliorating of immune system actions, and 
control of homeostasis in the various tissues [11, 12]. 
Furthermore, melatonin acts as an antioxidant and 
oncostatic attributes [13]. Several evidence revealed the 
repressing effects of melatonin against many types of 
tumors including breast, endometrium, prostate, ovary, 
intestine, and liver [14–19]. Bone metabolism is related 
to the levels of melatonin which lead to the prevention 
of bone degradation and the progression of bone forma-
tion [13]. Given that the reduction of melatonin levels in 
the specific time points, is associated with high incidence 
of osteosarcoma. Thus, it seems that melatonin acts as a 
potential anti-osteosarcoma. Here, we focused on osteo-
sarcoma-related molecular mechanisms affected by mel-
atonin. Moreover, we highlighted the different findings of 
pre-clinical researches on anti- osteosarcoma effects of 
melatonin.
Osteosarcoma pathogenesis: insights in molecular 
mechanisms
Osteosarcoma is associated with a complex of numeri-
cal and structural chromosomal abnormalities and an 
unstable genome [20]. Many amplifications and dele-
tions occurred in different regions of the genome. For 
example, 1q23.1–1q21.1, 1p35, 19p13.11–19p13.2, 
and 6p22.1–6p21.31 amplified whilst 5q14.3–5q22.2, 
13q13.2–13p14.3, and 5q12.3–5q13.2 are deleted [21, 
22]. It has been showed that these modifications and 
deletions are related with deregulation of a sequence of 
molecular targets such as rapamycin (mTOR) and vascu-
lar endothelial growth factor (VEGF), cellular adhesion 
molecules, wingless-type MMTV integration site fam-
ily (Wnt), and Hedgehog signaling pathways [21]. One 
of the other aspects of osteosarcoma progression is the 
inactivation of tumor suppressor genes. For example, the 
alterations in tumor protein p53 (TP53) and retinoblas-
toma 1 (Rb1) in sporadic osteosarcoma is approximately 
30 to 40 present [20]. The Rb gene mutations resulted in 
the enhanced function of the transcription factor E2F. 
In primary osteosarcoma, the high levels of E2F1 have 
growth- suppressing effects such as p73 induction [23]. 
The reduced expression of WW domain-containing oxi-
doreductase (WWOX) in many cancers which acts as a 
tumor suppressor, is related to aggressive properties and 
low prognosis [24]. The deletion of the WWOX gene is 
observed in 30% of osteosarcoma cases which likely is an 
initial event in osteosarcoma pathogenesis [20].
BCL2-related to athanogene 3 (BAG3) is able to change 
the interaction between inhibitor of kappa B kinase 
gamma (IKK-g) and heat shock protein 70 (HSP70) and 
causes enhancing the accessibility of IKK-g which results 
in increasing of nuclear factor kappa B (NF-kB) activity 
and increasing survival [25]. These results suggested that 
BAG3 could be used as a potential therapeutic candidate 
in the treatment of osteosarcoma [25]. Bcl-xL downregu-
lation significantly decreased the proliferation of osteo-
sarcoma cells, while its upregulation could increase the 
cell proliferation [26]. Some studies indicated that the 
radiosensitivity and chemosensitivity are remarkably 
enhanced due to the downregulation of Bcl-xL which is 
related to elevating of caspase-3 function [26]. In osteo-
sarcoma cells, midkine is extremely expressed. The 
silencing of Midkine induces apoptosis, while recombi-
nant midkine enhances the cell proliferation [22]. One of 
the signaling networks involved in osteosarcoma is VEGF 
with a range of 74.1% of expression. So, treatment based 
on anti-vascular effects may be useful for osteosarcoma 
[21]. In addition to genetic mutations and damage of can-
cer suppressor genes, osteosarcoma associated with other 
factors that promulgate proliferation and metastasis [27]. 
The TGF-b protein, one member of the superfamily of 
five isoforms (TGF-b1–5), has a mitogenic efficacy on 
osteosarcoma cell lines [28]. One of the factors which 
were identified in the development of osteosarcoma is 
the change in the insulin-like growth factor-I (IGF-RI) 
receptor pathway [29, 30]. The IGF-RI, IGF-I/II com-
plex results in a reduction of expression MAPK/ERK and 
PI3K/Akt/mTOR cascades which promotes migration, 
proliferation, and survival [31]. A study has reported that 
overexpression of IGF-I, IGF-IR, and IGF-II in a consid-
erable ratio of osteosarcoma early tumors was observed 
[32]. Metastatic osteosarcoma is a set of genetic altera-
tions that results in the migration of tumor cells into 
the bloodstream, inhibition of apoptosis, and proliferate 
in other tissues [33]. In the Metastasis of osteosarcoma 
src and Wnt/B-catenin pathways have been involved. 
Moreover, it was identified a high expression of Notch1 
and Notch2 receptors in extremely metastatic osteosar-
coma specimens [34]. Also, the elimination of the Fas/Fas 
ligand pathway leads to apoptosis suppression and devel-
oping of osteosarcoma metastases [33]. Figure  1 illus-
trates different steps from ontogenesis to osteosarcoma.
Anti‑tumor effects of melatonin
Melatonin is an indoleamine which secreted by the pin-
eal gland and likely other organs [35]. Melatonin can have 
multiple functions through receptor-dependent mecha-
nisms and vice versa [36]. It is proven that melatonin has 
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anti-inflammatory and antioxidant activities. Melatonin 
acts as a scavenger factor and also enables to the regu-
lation of antioxidant enzyme and antioxidant enzyme 
activity [37]. It has been made clear that melatonin pos-
sesses a set of anti-cancer properties including antioxi-
dant, cytostatic, anti-proliferative, pro-apoptotic, and 
different functions related to its capacity to control epi-
genetic responses (Fig. 2) [38–41]. In vitro investigations 
reported that melatonin prevents proliferative ERK1/2 
signaling which is a pathway in the modulation of cell 
division [42]. Notably, melatonin results in activation of 
ERK1/2 signaling in natural cells, on the contrary, it is 
able to inhibit ERK1/2 in tumor cells, preventing prolif-
eration and decrease the resistance to cancer chemother-
apy [43].
Another pre-clinical study, supported the melatonin 
exerts a cytostatic effect which lead to the cell accumula-
tion in the G0/G1 phase or delaying in the entry to the S 
phase [44]. Shen et al. [45] demonstrated that melatonin 
induced the number of cells in the G1 phase but dimin-
ished those in the S phase. Another study was shown the 
cycle detention and apoptosis occurred after the admin-
istration of melatonin in the HepG2 cell line [46]. An 
important aspect of the anti-tumor effect of melatonin is 
its ability to induce apoptosis. Melatonin induces apop-
tosis just in tumor cells and leads to decreasing tumor 
cell size [47]. In a study on ovarian cancer, it was shown 
that melatonin causes increasing expression levels of 
the cleaved caspase 3, Bax, p53, and decreasing expres-
sion levels of Bcl-2, thus progresses apoptosis [48]. Wang 
J et  al. [15] evaluated the effect of melatonin on MDA-
MB-361 breast cancer cells. Results indicated that mela-
tonin had pro-apoptotic effects which were accompanied 
via increasing of APAF 1 expression by simultaneously 
repressing the p300/NF-κB, COX-2/PGE2, and PI3K/
Akt signaling. Melatonin is able to induce the releasing 
of cytochrome c and stimulated activities and cleavage of 
caspase 9 and 3.
Fig. 1 Pathogenesis of osteosarcoma
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In another study, it was observed that caspase 3, 9, 
6, and 7 were activated and melatonin also increased 
the Bax expression levels and induces the liberation 
of cytochrome c [49]. Recently, efforts have shifted 
to discover the role of melatonin in the prevention of 
tumor metastasis [50]. In several types of cancer, it has 
been indicated that melatonin has also significant anti-
metastatic effects such as its capacity to prevent the 
epithelial-to-mesenchymal transition (EMT) [51]. The 
modulation of cell–matrix, cytoskeletal reorganization, 
and prohibition of angiogenesis are other anti-metastatic 
mechanisms affected by melatonin [52–54]. The epider-
mal growth factor receptor 2 (HER2) alongside Mapk/
Erk signaling leads to the enhancement of metastasis 
and invasiveness of cancer cells. Utilization of mela-
tonin considerably decreased the function of Mapk/Erk 
signaling [41]. Also, melatonin exerts its anti-invasive 
activity though down regulation of the p38 pathway and 
detention of activity and expression of metalloprotein-
ases-2 and -9 [55]. Other beneficial actions of melatonin 
in cancer therapy are including reduction of oxida-
tive stress and toxicity due to chemotherapy and radio-
therapy [56]. In addition, emerging data is showing that 
melatonin shows weak or no anti-cancer effects [57–59]. 
These studies indicated that melatonin could not be used 
as first line therapeutic agent in the treatment of vari-
ous cancers. These studies recommended that melatonin 
could be employed as adjuvant therapy in combination 
with primary treatment agents and platforms.
Melatonin effects on bone cancer
The effects of melatonin on bone cancers open attractive 
horizons for many researchers. In this regards, several 
experimental studies have been conducted to assess the 
underlined mechanisms affected by melatonin in bone 
cancers. It is proven that bone metabolism is associated 
Fig. 2 Melatonin and its anti-cancer effects
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with melatonin levels. Melatonin has an effect on bone-
linked cell proliferation [60, 61]. It has been showed that, 
in the specific time points, the levels of melatonin are 
low and it is related to high incidence of osteosarcoma. 
These finding hypotheses that melatonin may have an 
inhibitory effects on osteosarcoma cells [62, 63]. Sev-
eral studies have shown the anti-proliferative effects of 
melatonin on the MG-63 osteosarcoma cells and have 
reported that the inhibitory activity of melatonin related 
to mitogen-activated kinases and AKT signaling [42, 63]. 
Melatonin interferes with the proliferation of osteosar-
coma cells via modulation of various signaling pathways. 
Melatonin specifically inhibits the phosphoactivation of 
ERK1/2 [42]. Also, these studies were demonstrated that 
the inhibitory function of melatonin correlated with the 
downregulation of cyclin CDK4 and D1 and of cyclin 
CDK1 and B1 [42, 63].
Liu et  al. [42] demonstrated that the combination 
of melatonin and PD98059, a selective inhibitor, had 
a duplicated effect for blocking ERK1/2 activity. One 
of the mechanisms affected by melatonin to suppress 
osteosarcoma cells is the induction of apoptosis. Garcia-
Santos et  al. [64] observed that melatonin could induce 
apoptosis in the Ewing’s sarcoma cell line. Similarly, an 
in vitro study reported that melatonin led to the induc-
tion apoptotic cell death by applying the Fas/FasL system 
in Ewing’s sarcoma. Various studies reported that mela-
tonin upregulated the death receptor Fas and its ligand 
FasL [64]. This study also revealed that melatonin could 
transiently increase the number of intracellular oxidants 
and also activate the redox-regulated transcription factor 
NF-kB [64]. Another study revealed that the combination 
of melatonin and vincristine could provide an acceptable 
synergistic effect and induced apoptosis via affecting on 
the extrinsic pathway in SK-N-MC cells. As well as, there 
was a significant enhancement in expression levels of cas-
pase-3, -8, -9 and Bid when melatonin/vincristinein com-
plex is used compared to the single treatments [6].
Another mechanism impacted by melatonin which 
can induce cell death, is SIRT1 inhibition [65]. SIRT1 is 
a nicotinamide adenine dinucleotide (NAD)-dependent 
deacetylase which plays an important role in carcinogen-
esis via deacetylation of main regulatory proteins such as 
p53 [66]. Cheng et al. [11] suggested that melatonin can 
inhibit cell growth in osteosarcoma through down-regu-
lation of SIRT1 signaling. Thus, the down-regulation of 
SIRT1 can be a therapeutic option for treatment of osteo-
sarcoma. Metastasis is very common cancer-related pro-
cess that there are approximately half of osteosarcoma 
patients [67]. A recent experimental study reported that 
melatonin strongly suppresses the invasion and migration 
of osteosarcoma cells. In addition, melatonin remarkably 
prohibits the sarcosphere organization of stem cells of 
osteosarcoma and regulates EMT markers of osteosar-
coma cells [68]. SOX9 as a very important transcription 
factor has a significant role in bone growth [69]. In vivo 
model showed that melatonin can significantly prevent 
the initiation and metastasis of osteosarcoma by down-
regulation of the SOX9-mediated signaling pathway [68]. 
In a study showed that melatonin could suppress C–C 
Table 1 Experimental studies that investigated the role of melatonin in bone cancer
Type of bone 
cancer
Form of melatonin Dosage Model Findings Ref
Osteosarcoma Melatonin loaded 
nanoparticles (PLGA)
3.9–500 mg/mL In vitro
(MG-63 cells)
Inhibition of MG-63 proliferation and decrease cell 
viability
[71]
Ewing sarcoma Melatonin combined 
with vincristine
50 µm–1 mM In vitro
(SK-N-MC cells)
Significant enhancement in the activation of Bid and 
caspase-3, -8, -9
[6]
Osteosarcoma Melatonin 1000 mM In vitro
(cell line SOSP-9607)
Reductions in GSH, tumor cell vitality, migration 
ability, adhesion ability, up-regulated acetylated-
p53 and down-regulated SIRT1 and increase in the 
apoptotic index
[11]
Osteosarcoma Melatonin 4 mM–10 mM In vitro
(MG-63 cells)
Inhibition of the MG-63 proliferation and downregula-
tion of cyclin D1,B1,E and CDK4, CDK1, CDK2
[63]
Osteosarcoma Melatonin/PD98059 
and melatonin
4 mM In vitro
(MG-63 cells)
Prohibition of the proliferation by significantly inhib-
ited phosphorylation of ERK1/2
[42]
Osteosarcoma Melatonin 0.25–2.0 mM In vitro
(U2OS cells)
Inhibition of the JNK pathway and reduction 
chemokine CCL24
[70]
Ewing sarcoma Melatonin 1 mM In vitro
(A-673, TC-71, A-4573 cells)
Reversion ewing sarcoma metabolic profile that was 
related to its cytotoxicity
[72]
Ewing sarcoma Melatonin 1 mM In vitro
(SK-N-MC, TC-71 A673, 
SK-ES1, A4573)
Expression of Fas and its ligand Fas L, activation of the 
redox-regulated transcription
factor Nuclear factor-kappaB and enhance in intracel-
lular oxidants
[64]
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motif chemokine ligand 24 (CCL24) genes’ expression in 
U2OS and HOS cell lines. The manipulation of CCL24 
levels affects osteosarcoma cells motility, invasion, and 
migration. Authors documented that melatonin was 
decreased the level of chemokine CCL24 via inhibition 
of the JNK pathway and subsequently preventing osteo-
sarcoma invasion. In this regards, it seems that melatonin 
has potential therapeutic candidate in the treatment 
of metastatic osteosarcoma [70]. Taken together, these 
results proposed that melatonin exerts anti-tumor effects 
against osteosarcoma using various pathways and mecha-
nisms (Table 1).
Conclusions
Osteosarcoma is known as high-grade primary bone 
malignancy. Despite the many available anti-tumor ther-
apies, the 5-year survival rate is only 60–70%. The differ-
ent strategies are used to treat osteosarcoma including 
the targeting of the altered transcription factors, cell pro-
liferation regulators, apoptosis targets, and angiogenesis 
modulators, to date, due to the side effects related to the 
established treatments, researchers try to find new or 
develop therapeutic platforms to overcome to these cur-
rent limitations. Due to the parallel incidence of osteo-
sarcoma and melatonin levels, this hormone could be 
introduced as a new candidate for the treatment of osteo-
sarcoma. Several experimental studies have reported the 
anti-cancer effects of melatonin against osteosarcoma. 
The results showed that melatonin can exert its anti-
tumor properties through activation/inhibition various 
mechanisms such as induction of apoptosis, anti-prolif-
erative, and anti-oxidant activities. Also, observing the 
positive effects of melatonin on preventing of the inva-
sion and migration of osteosarcoma cells to other organs 
is a promising therapeutic strategy to the prevent oste-
osarcoma metastasis. Collectively, melatonin alone or 
in combination with other therapeutic agents may be a 
good option for osteosarcoma cancer treatment.
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